Evommune (NYSE:EVMN) Director Acquires 10,000 Shares of Stock

Evommune, Inc. (NYSE:EVMN) Director Arthur Kirsch purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were bought at an average cost of $13.30 per share, with a total value of $133,000.00. Following the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $133,000. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Evommune Stock Down 0.7%

Shares of EVMN traded down $0.09 during mid-day trading on Wednesday, reaching $13.25. The company had a trading volume of 1,142,282 shares, compared to its average volume of 1,313,826. The firm has a fifty day simple moving average of $20.83 and a 200-day simple moving average of $22.10. Evommune, Inc. has a fifty-two week low of $12.07 and a fifty-two week high of $33.20.

Evommune (NYSE:EVMN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. Analysts forecast that Evommune, Inc. will post -2.83 earnings per share for the current year.

Institutional Trading of Evommune

Hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new stake in Evommune during the 4th quarter valued at $34,000. Strs Ohio bought a new position in Evommune during the first quarter valued at about $41,000. The Manufacturers Life Insurance Company acquired a new position in Evommune during the fourth quarter worth about $179,000. XTX Topco Ltd acquired a new position in Evommune in the fourth quarter worth approximately $321,000. Finally, Oxford Asset Management LLP bought a new position in shares of Evommune in the fourth quarter valued at $335,000.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on EVMN shares. Raymond James Financial lowered Evommune from a “strong-buy” rating to a “moderate buy” rating in a research note on Monday, June 29th. Morgan Stanley decreased their price target on Evommune from $55.00 to $26.00 and set an “overweight” rating for the company in a report on Tuesday, June 30th. Oppenheimer started coverage on Evommune in a research report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 target price on the stock. Clear Str upgraded Evommune to a “strong-buy” rating in a research note on Tuesday, March 17th. Finally, Weiss Ratings downgraded Evommune from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $45.62.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.